A
AVTX
Avalo Therapeutics Inc
14.21
-1.76-11.02%After Hours: 13.91 -0.30 -2.11%18:17 02/20 EST
OPEN/PREV CLOSE15.64/15.97
TODAY RANGE14.19-16.11
VOL431.15K
MARKET CAP257.68M
52 WEEK RANGE3.390-20.72
AVG VOL (3M)350.20K
% TURNOVER2.38%
TURNOVER--
P/E (TTM)-1.6162
% RANGE11.99%
EPS(TTM)-8.7920
P/E(FORWARD)-2.0959
P/B2.767
BVPS5.14
DIVIDEND--
P/S337.53
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP226.15M
SHARES OUTSTANDING18.13M
NEXT EARNINGS03/18-03/23
FREE FLOAT15.91M
LOT SIZE1
EX-DATE12/29/2023
News
Press Releases
Financial Reports
Profile
Reuters·2d ago
Cybin Appoints Michael Cola as CEO
TipRanks·02/12 15:40
Psychedelic: Clearmind reports additional CMND-100 safety results
TipRanks·02/04 12:57
Piper Sandler Keeps Their Buy Rating on Avalo Therapeutics (AVTX)
Reuters·02/04 12:00
Avalo Therapeutics nimmt an Investorenkonferenzen teil
Benzinga·02/02 19:25
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case
Benzinga·02/02 16:04
This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Dow Jones·02/02 14:34
Avalo Therapeutics Price Target Announced at $50.00/Share by Guggenheim
TipRanks·02/02 11:41
Guggenheim starts Avalo at Buy on hidradenitis suppurativa potential
TipRanks·02/02 11:15
Avalo Therapeutics initiated with a Buy at Guggenheim
TipRanks·01/26 14:46
Avalo Therapeutics management to meet with Piper Sandler
TipRanks·01/21 20:45
Avalo Therapeutics management to meet with Cantor Fitzgerald
Same Industry
Name/Symbol
Change%
Price